Mon panier

VEGF-D

VEGF-D Informations sur la molécule

Nom anglaisVascular endothelial growth factor DNombre de médicaments commercialisés0
Nombre de médicaments cliniques2Alias de la cibleC-Fos Induced Growth Factor (Vascular Endothelial Growth Factor D),FIGF,c-Fos-induced growth factor,VEGFD,VEGF-D,Vascular Endothelial Growth Factor D
Phase de R&D la plus avancéePhase 2 Clinical
Nom anglaisVascular endothelial growth factor D
Alias de la cibleC-Fos Induced Growth Factor (Vascular Endothelial Growth Factor D),FIGF,c-Fos-induced growth factor,VEGFD,VEGF-D,Vascular Endothelial Growth Factor D
Nombre de médicaments commercialisés0
Nombre de médicaments cliniques2
Phase de R&D la plus avancéePhase 2 Clinical

VEGF-D Liste de produits

  • Attribut

    Protein (5)

  • Bibliothèque de produits

    En ligne (5)

  • Espèces

    Human (2)Cynomolgus (1)Mouse (2)

  • Étiquette

    His Tag (2)His Tag & Avi Tag (2)Fc Tag (1)

  • Marqueur

    Unconjugated (3)Biotin-labeled (2)

VEGF-DContexte de la molécule

Vascular endothelial growth factor D (VEGF-D) is also known as C-fos induced growth factor (FIGF), which belongs to the PDGF / VEGF growth factor family and is active in angiogenesis, lymphangiogenesis, and endothelial cell growth, stimulating their proliferation and migration and also has effects on the permeability of blood vessels. This secreted protein VEGF-D / FIGF undergoes a complex proteolytic maturation, generating multiple processed forms that bind and activate VEGFR-2 and VEGFR-3. The structure and function of this protein is similar to those of VEGFC. FIGF / VEGF-D is highly expressed in lung, heart, small intestine and fetal lung. FIGF / VEGF-D may function in the formation of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Binds and activates VEGFR-2 (KDR / FLK1) and VEGFR-3 (FLT4) receptors.

VEGF-DAlias de la molécule

FIGF,VEGFD

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
EG-016EG-016; Ad-VEGF-APhase 2 ClinicalArk Therapeutics LtdPeripheral Vascular Diseases
Details
EG-011EG-011; Ad-VEGF-DPhase 2 ClinicalArk Therapeutics LtdAngina Pectoris
Details
  • Informations sur la molécule
  • Liste de produits
  • Informations sur les médicaments cliniques